 |
|
|
|
|
|
|
|
Marketed RX's
Teikoku was responsible for developing the first analgesic and anti-inflammatory plaster. Since then, we have expanded our portfolio. Here are some of the products that we have successfully developed:
 |
|
Product: Flector EP® 2 (Diclofenac Epolamine)
Co-developed with IBSA, this hydrogel patch is marketed throughout Europe for minor sports injuries under various brand names—including Flector EP® and Voltapatch® by IBSA and Novartis respectively.
|
|
 |
|
Product: Lidoderm® 1 (Lidocaine)
The first and only prescription hydrogel-patch approved in the United States for post-herpetic neuralgia (PHN). Teikoku partnered with Endo Pharmaceuticals to market the product in North America and with IBSA in Switzerland.
|
|
 |
|
Product: Seltouch (felbinac)
Co-developed with Wyeth, this product is marketed in Japan for osteoarthritis.
|
|
|
|
|
|
|
 |
Copyright © 2006 Teikoku Pharma USA, Inc. All Rights Reserved.
Teikoku Pharma USA, Teikoku, Teikoku Pharma, Teikoku Seiyaku Co., drug delivery systems, TDS, patches, unit-dose jellies, unit-dose liquids, creams and ointments, delivery products, pain management, cosmetic care, TDS technologies, patent protections, prescription, otcs, medical device market, applications, transdermal drug delivery technologies, Lidoderm, Endo Pharmaceuticals, post-herpetic neuralgia, TDS-based health and beauty products, face masks, anti-wrinkle patches, skin whiteners, and cuticle softe
|
|
Teikoku Brochure